Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Norditek in conjunction with its listing on Nasdaq First North
Mandate

Vinge advises Norditek in conjunction with its listing on Nasdaq First North

November 10, 2021 Capital Markets and Public M&A

Vinge has advised Norditek Group AB in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 10 November 2021. In connection with the listing, an invitation to subscribe for shares for a subscription price of SEK 11 was implemented, which was significantly oversubscribed by approximately 4.5 times.

Norditek Group is an environment technology company which focuses on mobile and flexible recycling stations in the fields of Waste, Sand & Rock and Biomass. The company both develops and sells stations by a tried and tested offering which facilitates cost reductions for its customers at the same time as the customers contribute to a more circular society.

Vinge’s team primarily consisted of Anders Strid, Jenny Sandlund (project manager), Beatrice Randow and Anna Högsten.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026